专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2367820B1 NOVEL ANTIMICROBIAL AGENTS 有权
标题翻译：新的抗菌物质
公开(公告)号：EP2367820B1
公开(公告)日：2016-09-21
申请号：EP09827270.1
申请日：2009-11-18
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , TREHAN, Sanjay , DAS, Jagattaran , KANWAR, Sandeep , MAGADI, Sitaram, Kumar , SHARMA, Sudhir, Kumar
IPC分类号： C07D413/10 , C07D413/14 , A61P31/04 , A61K31/496 , C07D263/20 , C07D417/12 , C07D487/04 , C07D413/12
CPC分类号： C07D487/04 , C07D263/20 , C07D413/12 , C07D413/14 , C07D417/12

2. 发明公开

EP2303299A2 COMPOSITIONS COMPRISING EUPHORBIA PROSTRATA AND PROCESS OF PREPARATION THEREOF 审中-公开
标题翻译：组合物匍匐大戟及其制造方法
公开(公告)号：EP2303299A2
公开(公告)日：2011-04-06
申请号：EP09754359.9
申请日：2009-05-28
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , SINGH, Sukhjeet , BHASIN, Shilpa
IPC分类号： A61K36/47 , A61K9/00 , A61P17/00
CPC分类号： A61K36/47 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/284 , A61K9/2886 , A61K9/4858 , A61K9/4866
摘要： Oral pharmaceutical compositions comprising dry extract of
Euphorbia prostrata from about 0.1% to about 99% by weight wherein the effective average particle size of the dry extract of
Euphorbia prostrata is not more than about 500 microns with pharmaceutically acceptable excipient(s) and process(s) for the preparation of such compositions useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease and the like are provided. Further, the pharmaceutical compositions of the present invention provides for the administration of a therapeutically and/or prophylactically effective amount of the
Euphorbia prostrata wherein the compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Furthermore, the compositions preferably provides a release of not less than about 50% of the dry extract of
Euphorbia prostrata in first 15 minutes and not less than about 80% of dry extract of
Euphorbia prostrata after total dissolution study of about 60 minutes when tested in accordance with the dissolution method described herein employing physiological pH range of about 2 to about 7.5 optionally with surfactant(s). Preferably the compositions of the present invention are in the form of tablets, minitablets, powders, capsules, pellets, granules, beads, compacts and the like. The present invention also provides and prophylactic and/or therapeutic methods of using such compositions for the treatment of anorectal diseases including hemorrhoids and colonic diseases.

3. 发明公开

EP2250157A1 NOVEL HETEROCYCLIC COMPOUNDS 失效转让
标题翻译：新的杂环化合物
公开(公告)号：EP2250157A1
公开(公告)日：2010-11-17
申请号：EP09703708.9
申请日：2009-01-23
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , TREHAN, Sanjay , SINGH, Nishan , NANDA, Gurmeet Kaur , MAGADI, Sitaram Kumar , SHARMA, Sudhir Kumar , DAS, Jagattaran
IPC分类号： C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04 , A61K31/551 , A61P3/10
CPC分类号： C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04
摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including
R and
S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV). Formula I

4. 发明授权

EP2250157B1 NOVEL HETEROCYCLIC COMPOUNDS 失效转让
标题翻译：新的杂环化合物
公开(公告)号：EP2250157B1
公开(公告)日：2014-11-05
申请号：EP09703708.9
申请日：2009-01-23
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , TREHAN, Sanjay , SINGH, Nishan , NANDA, Gurmeet Kaur , MAGADI, Sitaram Kumar , SHARMA, Sudhir Kumar , DAS, Jagattaran
IPC分类号： C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04 , A61K31/551 , A61P3/10
CPC分类号： C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04

5. 发明公开

EP2384338A2 GLP-1 ANALOGS AND USES THEREOF 审中-公开
标题翻译： GLP-1类似物及其用途
公开(公告)号：EP2384338A2
公开(公告)日：2011-11-09
申请号：EP09836180.1
申请日：2009-12-24
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , VINAYAK, Virender Kumar , PRASAD, Sudhanand
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00
摘要： The present invention relates to a peptide selected from a group comprising GLP-1 analogs, its truncated forms, or pharmaceutically acceptable salts and derivatives thereof. The present invention further relates to a peptide selected from a group comprising GLP-1 analogs, its truncated forms, or pharmaceutically acceptable salts and derivatives thereof, wherein one or more aminoacids are substituted with a non-coded aminoacid.

6. 发明公开

EP2615913A2 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN 审中-公开
标题翻译： PREGABALINHALTIGE PHARMAZEUCHSCHE ZUSAMMENSETZUNGEN MITVERZÖGERTERFREISETZUNG
公开(公告)号：EP2615913A2
公开(公告)日：2013-07-24
申请号：EP11824691.7
申请日：2011-09-15
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , SINGH, Sarabjit , PUTHLI, Shivanand
IPC分类号： A01N37/12 , A61K31/195
CPC分类号： A61K9/0002 , A61K9/1623 , A61K9/2018 , A61K9/2054 , A61K31/197 , A61K47/26
摘要： The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.
摘要翻译：本发明涉及稳定的每日一次的持续释放药物组合物，其包含普瑞巴林或其药学上可接受的盐和药学上可接受的赋形剂，其中药物组合物与普通巴布林常规立即释放制剂每天两次生物等效。本发明还涉及包含普瑞巴林和糖酯作为释放阻滞剂的组合物，其用于保持药物的均匀释放速率和用于制备这种口服持续释放制剂的方法。

7. 发明公开

EP2361094A1 COMBINATION VACCINE WITH WHOLE CELL PERTUSSIS 审中-公开
标题翻译： GZZELLELLER PERTUSSIS-KOMBINATIONSIMPFSTOFF
公开(公告)号：EP2361094A1
公开(公告)日：2011-08-31
申请号：EP09821705.2
申请日：2009-10-23
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , SINGH, Sukhjeet , JAMBU, Lavit
IPC分类号： A61K39/05 , A61K39/08 , A61K39/10 , A61K39/102 , A61K39/13 , A61K39/29
CPC分类号： A61K39/0018 , A61K39/05 , A61K39/08 , A61K39/099 , A61K39/102 , A61K39/12 , A61K39/13 , A61K39/292 , A61K2039/5252 , A61K2039/55505 , A61K2039/70 , C12N2730/10134 , C12N2770/32634 , Y02A50/466
摘要： The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, whole cell pertussis and polio. The present invention also relates to inclusion of one or more antigens in the said combination vaccine, for protection against infections caused by Haemophilus influenzae, Hepatitis virus, and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

8. 发明公开

EP2187872A1 EXTENDED RELEASE COMPOSITIONS COMPRISING MYCOPHENOLATE SODIUM AND PROCESSES THEREOF 审中-公开
标题翻译：组合物麦考酚钠缓释剂和及其方法
公开(公告)号：EP2187872A1
公开(公告)日：2010-05-26
申请号：EP08789927.4
申请日：2008-08-11
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , SINGH, Sukhjeet , DEVARAJAN, Sampath Kumar
IPC分类号： A61K9/22 , A61K31/341 , A61K31/365
CPC分类号： A61K9/2077 , A61K9/2013 , A61K9/2846 , A61K31/365
摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The composition of the present indention are safe, effective and well-tolerated, and are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).
摘要翻译：延长释放药物组合物，包含霉酚酸钠作为活性药剂，worin所述组合物显示出特征性释放曲线当经历体外溶出研究，并worin所述霉酚酸钠被释放以持续方式在体内用于搜索一个持续时间延长量没有实质上减轻或至少减少而不损害活性剂。所述的生物利用度被设置引起任何相关胃肠副作用（多个）的可能性。因此，本发明提供了一种制备剂型的组合物和使用寻求剂型的预防和/或治疗方法的过程中，本发明的组合物是用于管理有用：例如预防，改善和/或治疗免疫抑制剂，说明疾病（一个或多个）/病症（一个或多个）的爱特别是对于治疗或预防器官，组织或细胞的同种异体移植物或异种移植物排斥，例如移植，或免疫介导疾病的管理（自身免疫疾病）之后。

9. 发明授权

EP1002531B1 A water-miscible composition of nimesulide 有权
标题翻译：尼美舒利的水的药物成分
公开(公告)号：EP1002531B1
公开(公告)日：2003-05-02
申请号：EP98308779.2
申请日：1998-10-27
申请人： PANACEA BIOTEC LIMITED
发明人： Singh, Amarjit , JAIN, Rajesh
IPC分类号： A61K31/18 , A61K31/63 , A61K9/08 , A61K47/10 , A61K47/18 , A61K47/20 , A61P29/00
CPC分类号： A61K47/20 , A61K9/0019 , A61K9/08 , A61K31/18 , A61K31/415 , A61K47/10 , A61K47/18 , A61K47/22 , A61K47/34

10. 发明公开

EP2362880A1 TUMOR NECROSIS FACTOR ALPHA INHIBITING PEPTIDES AND USES THEREOF 审中-公开
标题翻译：肿瘤坏死因子α-炎性肽及其用途
公开(公告)号：EP2362880A1
公开(公告)日：2011-09-07
申请号：EP09827268.5
申请日：2009-11-05
申请人： Panacea Biotec Limited
发明人： JAIN, Rajesh , VINAYAK, Virendra Kumar , DUBEY, Shweta , PRASAD, Sudhanand , GOEL, Vijay , JAIN, Rahul
IPC分类号： C07K14/47 , C07K14/525 , C07K5/06 , C07K5/08
CPC分类号： C07K5/0812 , C07K5/081 , C07K5/0819 , C07K5/123
摘要： The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF - alpha mediated inflammatory disorders.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式